Daniel Kelly Benjamin, MD, PhD

Dr. Danny Benjamin is the Principal Investigator and Chair of the National Institute of Child Health and Human Development’s Pediatric Trials Network. The Network is responsible for designing and leading clinical trials of off-patent medicines in children of all ages across all therapeutic areas. The team has established, or is actively studying, the correct dosing and safety of more than 50 of the most commonly used medicines in children. Each of these trials is conducted under an investigational new drug (IND) application with guidance from the Food and Drug Administration for labeling.

Signature programs of the Network include clinical trials in premature, term infants and most recently, obese children. Over the past 10 years, Dr. Benjamin’s group has enrolled more premature infants, at more sites, in more clinical trials of off-patent anti-infectives under an IND than all other academic medical centers, pharmaceutical companies, and government agencies in the world, combined.

Dr. Benjamin is recognized by the National Institutes of Health as a premiere mentor and educator. His research program serves as a platform to train students and early career investigators. Dr. Benjamin’s group has a clinical research summer program for high school and college students targeting under-represented minority students, and he is the primary mentor for medical students, residents, subspecialty fellows (including two T32 programs sponsored by NIH for which he is PI), and multiple junior faculty.

Dr. Benjamin has published over 250 works with up to 7000 citations.